About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. Learn More
Investor Information
Investor Information
News Releases
- 21 DEC 11 Santarus Adds FENOGLIDE to Marketed Products Portfolio
- 20 DEC 11 Santarus Submits New Drug Application to FDA for UCERIS (budesonide) Tablets
- 6 DEC 11 Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress
- More News
Products
-
CYCLOSET® (bromocriptine mesylate) is a first-in-class antidiabetic treatment that may lower your blood sugar, without increasing insulin. -
GLUMETZA® (metformin hydrochloride extended release tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As with all metformin products, GLUMETZA has a boxed warning for lactic acidosis. Please click here for Important Safety Information and Full Prescribing Information, including boxed warning. -
ZEGERID® (omeprazole/sodium bicarbonate) is an immediate-release oral proton pump inhibitor (PPI) used in adults for up to 4 weeks to treat heartburn and other symptoms that happen with gastroesophageal reflex disease (GERD).
Pipeline
Learn More Have Questions? Request Medical Information